Pembrolizumab in patients with extensive-stage small-cell lung cancer: Results from the phase Ib KEYNOTE-028 study

Journal of Clinical Oncology

Volumn 35, Issue 34, 2017, Pages 3823-3829

  Ott, Patrick A ^a   Elez, Elena ^b   Hiret, Sandrine ^c   Kim, Dong Wan ^d   Morosky, Anne ^e   Saraf, Sanatan ^e   Piperdi, Bilal ^e   Mehnert, Janice M ^f  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b VALL D'HEBRON INSTITUTE OF ONCOLOGY   (Spain)

^c UMR INSERM U892 CNRS 6299   (France)

^d Seoul National University Hospital   (South Korea)

^e MERCK RESEARCH LABORATORIES   (United States)

^f RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; AUTOIMMUNE THYROIDITIS; BILIRUBIN BLOOD LEVEL; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COLITIS; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; EPIPHORA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INFUSION RELATED REACTION; INSOMNIA; INTESTINE ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NATIONAL HEALTH ORGANIZATION; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SIDE EFFECT; SMALL CELL LUNG CANCER; STROMA; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; B7-H1 ANTIGEN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; SMALL CELL LUNG CARCINOMA; SURVIVAL ANALYSIS;

EID: 85035799251     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Pesch B, Kendzia B, Gustavsson P, et al: Cigarette smoking and lung cancer: Relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer 131:1210-1219, 2012
2. Alvarado-Luna G, Morales-Espinosa D: Treatment for small cell lung cancer: Where are we now? A review. Transl Lung Cancer Res 5:26-38, 2016
3. Hurwitz JL, McCoy F, Scullin P, et al: New advances in the second-line treatment of small-cell lung cancer. Oncologist 14:986-994, 2009
4. Rossi A, Di MM, Chiodini P, et al: Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: The COCIS meta-analysis of individual patient data. J Clin Oncol 30: 1692-1698, 2012
5. National Comprehensive Cancer Network: Guidelines: Small-cell lung cancer, 2016. 2016
6. Fruh M, De Ruysscher D, Popat S, et al: Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(suppl 6):vi99-vi105, 2013
7. Okuma HS, Horinouchi H, Kitahara S, et al: Comparison of amrubicin and weekly cisplatin/ etoposide/irinotecan in patients with relapsed small-cell lung cancer. Clin Lung Cancer 18:234-240, 2017
8. Bronte G, Rizzo S, La Paglia L, et al: Driver mutations and differential sensitivity to targeted therapies: A new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev 36:S21-S29, 2010
9. Luo SY, Lam DCL: Oncogenic driver mutations in lung cancer. Transl Respir Med 1:6, 2013
10. Sul J, Blumenthal GM, Jiang X, et al: US Food and Drug Administration approval summary: Pembrolizumab for the treatment of patients with metastatic non–small-cell lung cancer whose tumors express programmed death-ligand 1. Oncologist 21:643-650, 2016
11. Spranger S, Spaapen RM, Zha Y, et al: Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 5:200ra116, 2013
12. Taube JM, Anders RA, Young GD, et al: Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4:127ra37, 2012
13. Sharma P, Allison JP: The future of immune checkpoint therapy. Science 348:56-61, 2015
14. Garon EB, Rizvi NA, Hui R, et al: Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med 372:2018-2028, 2015
15. Herbst RS, Baas P, Kim DW, et al: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non–small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 387:1540-1550, 2016
16. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
17. Larkin J, Chiarion-Sileni V, Gonzalez R, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23-34, 2015
18. Dolled-Filhart M, Roach C, Toland G, et al: Development of a companion diagnostic for pembrolizumab in non–small-cell lung cancer using immunohistochemistry for programmed death ligand-1. Arch Pathol Lab Med 140:1243-1249, 2016
19. Robert C, Schachter J, Long GV, et al: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521-2532, 2015
20. Hamid O, Robert C, Daud A, et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134-144, 2013
21. Antonia SJ, Lopez-Martin JA, Bendell J, et al: Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A mul-ticentre, open-label, phase 1/2 trial. Lancet Oncol 17: 883-895, 2016
22. Wu P, Wu D, Li L, et al: PD-L1 and survival in solid tumors: A meta-analysis. PLoS One 10:e0131403, 2015
23. Reference deleted.
24. Ardizzoni A, Hansen H, Dombernowsky P, et al: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease—The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 15:2090-2096, 1997
25. Asai N, Ohkuni Y, Kaneko N, et al: Relapsed small-cell lung cancer: Treatment options and latest developments. Ther Adv Med Oncol 6:69-82, 2014
26. Reck M, Luft A, Szczesna A, et al: Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol 34:3740-3748, 2016
27. Atkins MB, Choueiri TK, Hodi F, et al: Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase I study. J Clin Oncol 33, 2015 (suppl; abstr 3009)
28. Ribas A, Puzanov I, Dummer R, et al: Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol 16:908-918, 2015
29. Reck M, Rodriguez-Abreu D, Robinson AG, et al: Pembrolizumab versus chemotherapy for PD-L1-positive non–small-cell lung cancer. N Engl J Med 375:1823-1833, 2016
30. Socinski M, Horn L, Steins M, et al: A phase 3 trial of nivolumab vs investigator’s choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage IV/recurrent programmed death ligand 1 (PD-L1)-positive NSCLC. Ann Oncol 27(suppl 6):vi552-vi587, 2016
31. Tumeh PC, Harview CL, Yearly JH, et al: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568-571, 2014
32. Rizvi NA, Hellmann MD, Snyder A, et al: Mutational landscape determines sensitivity to PD-1 blockade in non–small-cell lung cancer. Science 348: 124-128, 2015
33. Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509-2520, 2015
34. Mehnert JM, Panda A, Zhong H, et al: Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest 126: 2334-2340, 2016
35. Johanns TM, Miller CA, Dorward IG, et al: Immunogenomics of hypermutated glioblastoma: A patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov 6:1230-1236, 2016
36. Rooney MS, Shukla SA, Wu CJ, et al: Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160:48-61, 2015